Eli Lilly surpasses Novo's golden diabetes drug
US pharmaceutical firm Eli Lilly has presented its long-awaited data for drug candidate tirzepatide in a direct comparison study with Novo Nordisk's semaglutide. The US candidate takes top prize.
BY BENJAMIN WERNER CHRISTENSEN, TRANSLATED BY NIELSINE NIELSEN
US firm Eli Lilly is well on the way to overtaking Danish pharmaceutical flagship Novo Nordisk.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg&w=384&q=75)
